How to buy Compugen stock

Compugen Ltd is a biotechnology business based in the US. Compugen shares (CGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Compugen employs 68 staff and has a trailing 12-month revenue of around 0.00.

Compugen share price

Use our graph to track the performance of CGEN stocks over time.

Compugen shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$7.10 - $19.90
50-day moving average	$8.67
200-day moving average	$11.72
Wall St. target price	$21.29
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.45

Buy Compugen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Compugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Compugen Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Compugen financials

Revenue TTM	$2 million
Gross profit TTM	$1.9 million
Return on assets TTM	-20.5%
Return on equity TTM	-37.57%
Profit margin	0%
Book value	$1.43
Market capitalisation	$712.7 million

TTM: trailing 12 months

Shorting Compugen shares

There are currently 7.4 million Compugen shares held short by investors – that's known as Compugen's "short interest". This figure is 2.1% down from 7.6 million last month.

There are a few different ways that this level of interest in shorting Compugen shares can be evaluated.

Compugen's "short interest ratio" (SIR)

Compugen's "short interest ratio" (SIR) is the quantity of Compugen shares currently shorted divided by the average quantity of Compugen shares traded daily (recently around 1.3 million). Compugen's SIR currently stands at 5.54. In other words for every 100,000 Compugen shares traded daily on the market, roughly 5540 shares are currently held short.

However Compugen's short interest can also be evaluated against the total number of Compugen shares, or, against the total number of tradable Compugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Compugen's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Compugen shares in existence, roughly 90 shares are currently held short) or 0.1118% of the tradable shares (for every 100,000 tradable Compugen shares, roughly 112 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Compugen.

Find out more about how you can short Compugen stock.

Compugen share dividends

We're not expecting Compugen to pay a dividend over the next 12 months.

Compugen share price volatility

Over the last 12 months, Compugen's shares have ranged in value from as little as $7.1 up to $19.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Compugen's is 2.3359. This would suggest that Compugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Compugen overview

Compugen Ltd. , a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd.

Frequently asked questions

• What percentage of Compugen is owned by insiders or institutions?

  Currently 0.292% of Compugen shares are held by insiders and 47.857% by institutions.

• How many people work for Compugen?

  Latest data suggests 68 work at Compugen.

• When does the fiscal year end for Compugen?

  Compugen's fiscal year ends in December.

• Where is Compugen based?

  Compugen's address is: Building D, Holon, Israel, 5885849

• What is Compugen's ISIN number?

  Compugen's international securities identification number is: IL0010852080

• What is Compugen's CUSIP number?

  Compugen's Committee on Uniform Securities Identification Procedures number is: M25722105